Search - tctmd.com

Displaying 121 - 140 of 168

Sort: Relevancy | Date

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Presentation JIM 2018

A New Generation Abluminal Coated Sirolimus Eluting Stent As A Treatment Option For Diabetic Patients

Presenter: Luca Testa

February 22, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Advertisement

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

TCTMD’s Top 10 Most Popular Stories for August 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

A New Generation Abluminal Coated Sirolimus Eluting Stent As A Treatment Option For Diabetic Patients

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content